Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
Authors' conclusion
The U-TXM was log-linearly independently associated with SVE-R in diabetes.
Study context
- Population
- People with type 1 or 2 DM and no CVD in the ASCEND trial (U-TXM measured pre-randomisation to aspirin or placebo)
- Participants
- 5,948 people
- Comparison
- Higher vs lower baseline urinary 11-dehydro-TXB2
- Primary endpoint
- Serious vascular events or revascularizations (SVE-R), major bleeding, cancer
- Follow-up
- 6.6 years
Primary result
As reported in the abstract
SVE-R, major bleed, cancer per 1 SD higher log U-TXM (adjusted)
Per 1 SD higher log U-TXMHazard ratio (95% CI)
SVE-R (n = 618 events)
1.09(1.00–1.18)
Major bleed (n = 206 events)
1.16(1.01–1.34)
Cancer (n = 700 events)
1.06(0.98–1.14)
Per 1 SD higher log U-TXM, as printed
Further findings
Correlates of higher U-TXM
- Higher U-TXM associated with older age, female sex, current smoking, T2DM, higher body size, urinary albumin/creatinine ratio ≥3 mg/mmol and higher eGFR
Original publication
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial. Eur Heart J. Published 22 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →